Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > What have we got here?

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 20, 2023 12:03pm

101 Views

Post# 35505389

RE:What have we got here?

ONCY's pelareorep activates the interferon (IFN) signalling pathway which stimulates the innate and adaptive immune system where gamma-delta (γδ) T cells, play a critical role in filling the gap needed for adaptive immune cells maturation, linking the innate and adaptive immunity together.

The AWARE-1 study results presented at SABC 2022 on December 07, 2022 demonstrated that pelareorep activated the IFN signalling pathway and "primes" the tumor in advance of immune checkpoint inhibition. (see below)

https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=35191525

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide